Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway
© 2023. Asian Pacific Association for the Study of the Liver..
BACKGROUND: Aberrant iron metabolism is commonly observed in multiple tumor types, including hepatocellular carcinoma (HCC). However, as the key regulator of iron metabolism involved in iron absorption, the role of transferrin receptor (TFRC) in HCC remains elusive.
METHODS: The mRNA and protein expression of TFRC were evaluated in paired HCC and adjacent non-tumor specimens. The correlation between TFRC level and clinicopathological features or prognostic significance was also analyzed. The role of TFRC on biological functions was finally studied in vitro and in vivo.
RESULTS: The TFRC level was remarkably upregulated in HCC tissues compared to paired peritumor tissues. Overexpressed TFRC positively correlated with serum alpha-fetoprotein, carcinoembryonic antigen, and poor tumor differentiation. Multivariate analysis demonstrated that upregulated TFRC was an independent predictive marker for poorer overall survival and disease-free survival in HCC patients. Loss of TFRC markedly impaired cell proliferation and migration in vitro and notably suppressed HCC growth and metastasis in vivo, while overexpression of TFRC performed an opposite effect. Mechanistically, the mTOR signaling pathway was downregulated with TFRC knockdown, and the mTOR agonist MHY1485 completely reversed the biological inhibition in HCC cells caused by TFRC knockdown. Furthermore, exogenous ferric citrate (FAC) or iron chelator reversed the changed biological functions and signaling pathway expression of HCC cells caused by TFRC knockdown or overexpression, respectively.
CONCLUSIONS: Our study indicates that TFRC exerts an oncogenic role in HCC and may become a promising therapeutic target to restrain HCC progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Hepatology international - 18(2024), 2 vom: 01. Apr., Seite 636-650 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Fu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12072-023-10607-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36474474X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36474474X | ||
| 003 | DE-627 | ||
| 005 | 20240418232342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12072-023-10607-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM36474474X | ||
| 035 | |a (NLM)37982952 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Fu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Asian Pacific Association for the Study of the Liver. | ||
| 520 | |a BACKGROUND: Aberrant iron metabolism is commonly observed in multiple tumor types, including hepatocellular carcinoma (HCC). However, as the key regulator of iron metabolism involved in iron absorption, the role of transferrin receptor (TFRC) in HCC remains elusive | ||
| 520 | |a METHODS: The mRNA and protein expression of TFRC were evaluated in paired HCC and adjacent non-tumor specimens. The correlation between TFRC level and clinicopathological features or prognostic significance was also analyzed. The role of TFRC on biological functions was finally studied in vitro and in vivo | ||
| 520 | |a RESULTS: The TFRC level was remarkably upregulated in HCC tissues compared to paired peritumor tissues. Overexpressed TFRC positively correlated with serum alpha-fetoprotein, carcinoembryonic antigen, and poor tumor differentiation. Multivariate analysis demonstrated that upregulated TFRC was an independent predictive marker for poorer overall survival and disease-free survival in HCC patients. Loss of TFRC markedly impaired cell proliferation and migration in vitro and notably suppressed HCC growth and metastasis in vivo, while overexpression of TFRC performed an opposite effect. Mechanistically, the mTOR signaling pathway was downregulated with TFRC knockdown, and the mTOR agonist MHY1485 completely reversed the biological inhibition in HCC cells caused by TFRC knockdown. Furthermore, exogenous ferric citrate (FAC) or iron chelator reversed the changed biological functions and signaling pathway expression of HCC cells caused by TFRC knockdown or overexpression, respectively | ||
| 520 | |a CONCLUSIONS: Our study indicates that TFRC exerts an oncogenic role in HCC and may become a promising therapeutic target to restrain HCC progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD71 | |
| 650 | 4 | |a FK506-binding protein 12-rapamycin-associated protein 1 | |
| 650 | 4 | |a HCC | |
| 650 | 4 | |a Iron metabolism | |
| 650 | 4 | |a Liver cancer | |
| 650 | 4 | |a Mammalian target of rapamycin | |
| 650 | 4 | |a TFRC | |
| 650 | 4 | |a Tumor progression | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 650 | 7 | |a Receptors, Transferrin |2 NLM | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a MTOR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 700 | 1 | |a Xu, Wei-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wan-Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ru-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jia-Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Guang-Cong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhi-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Zhuo-Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Shu-Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Xi-Zhong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tao-Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Ji-Min |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology international |d 2007 |g 18(2024), 2 vom: 01. Apr., Seite 636-650 |w (DE-627)NLM190585528 |x 1936-0541 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:2 |g day:01 |g month:04 |g pages:636-650 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12072-023-10607-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 2 |b 01 |c 04 |h 636-650 | ||